[go: up one dir, main page]

PE20080944A1 - Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5) - Google Patents

Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)

Info

Publication number
PE20080944A1
PE20080944A1 PE2007000907A PE2007000907A PE20080944A1 PE 20080944 A1 PE20080944 A1 PE 20080944A1 PE 2007000907 A PE2007000907 A PE 2007000907A PE 2007000907 A PE2007000907 A PE 2007000907A PE 20080944 A1 PE20080944 A1 PE 20080944A1
Authority
PE
Peru
Prior art keywords
pyridin
alk
pyrimidine derivatives
kinase receptor
receptor inhibitors
Prior art date
Application number
PE2007000907A
Other languages
English (en)
Inventor
Catherine Leblanc
Maude Nadine Pierrette Pipet
Robin Alec Fairhurst
Claire Adcock
Robert Alexander Pulz
Nikolaus Johannes Stiefl
Duncan Shaw
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080944(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06117227A external-priority patent/EP1878733A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080944A1 publication Critical patent/PE20080944A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIMIDINA DE FORMULA (I), EN DONDE T1 ES UN GRUPO HETEROCICLICO DE 4 A 14 MIEMBROS SUSTITUIDO O NO SUSTITUIDO; T2 ES UN GRUPO HETEROCICLICO DE 4 A 14 MIEMBROS SUSTITUIDO O NO; Ra Y Rb SON H, ALQUILO(C1-C8), CICLOALQUILO(C3-C10); ENTRE OTROS. SON PREFERIDOS: (1H-INDOL-4-IL-METIL)-(6-PIRIDIN-3-IL-2-PIRIDIN-2-IL-PIRIMIDIN-4-IL)-AMINA; [2-(1H-INDOL-4-IL)-ETIL]-(6-PIRIDIN-3-IL-2-PIRIDIN-2-IL-PIRIMIDIN-4-IL)-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR DE CINASA ACTIVINA(ALK-5) Y POR LO CUAL SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS, HIPERTENSION PULMONAR, FIBROSIS PULMONAR
PE2007000907A 2006-07-14 2007-07-13 Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5) PE20080944A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117227A EP1878733A1 (en) 2006-07-14 2006-07-14 Pyrimidine derivatives as ALK-5 inhibitors
EP06119564 2006-08-25

Publications (1)

Publication Number Publication Date
PE20080944A1 true PE20080944A1 (es) 2008-09-02

Family

ID=38515726

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000907A PE20080944A1 (es) 2006-07-14 2007-07-13 Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)

Country Status (17)

Country Link
US (1) US7989458B2 (es)
EP (1) EP2044056B1 (es)
JP (1) JP4960450B2 (es)
KR (1) KR101172936B1 (es)
AR (1) AR061974A1 (es)
AU (1) AU2007271964B2 (es)
BR (1) BRPI0714409A2 (es)
CA (1) CA2657227A1 (es)
CL (1) CL2007002043A1 (es)
ES (1) ES2393932T3 (es)
MX (1) MX2009000310A (es)
PE (1) PE20080944A1 (es)
PL (1) PL2044056T3 (es)
PT (1) PT2044056E (es)
RU (1) RU2485115C2 (es)
TW (1) TW200821297A (es)
WO (1) WO2008006583A1 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP5256043B2 (ja) 2005-12-02 2013-08-07 アイシス ファーマシューティカルズ， インコーポレーテッド 複数の置換基を有する抗菌４，５−置換アミノグリコシドアナログ
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
TW200924770A (en) 2007-11-06 2009-06-16 Astrazeneca Ab Novel compounds 089
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
PT2231642E (pt) * 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
SG10201808863UA (en) 2008-03-17 2018-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
BRPI0911490A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5)
WO2009146408A1 (en) * 2008-05-30 2009-12-03 Summa Health Systems Llc Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010030690A1 (en) 2008-09-10 2010-03-18 Isis Pharmaceuticals, Inc. Antibacterial 4,6-substituted 6', 6" and 1 modified aminoglycoside analogs
WO2010042850A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010042851A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
US9468649B2 (en) 2008-12-05 2016-10-18 The Regents Of The University Of California Methods of treating epilepsy with transforming growth factor beta inhibitors
EP2373784B1 (en) 2008-12-17 2017-10-25 The Scripps Research Institute Generation and maintenance of stem cells
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
MX2012004036A (es) 2009-10-09 2012-06-27 Achaogen Inc Analogos de aminoglicosidos antibacterianos.
AU2010306750B2 (en) 2009-10-15 2014-11-13 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
CN102741394B (zh) 2009-10-16 2016-05-04 斯克里普斯研究所 多能细胞的诱导
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
ES2986590T3 (es) 2010-06-14 2024-11-12 Scripps Research Inst Reprogramación de células hacia un nuevo destino
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
JP2013542992A (ja) 2010-11-17 2013-11-28 アカオジェン インコーポレイテッド 抗菌性アミノグリコシド類似体
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
CA2904641C (en) 2013-03-12 2021-07-20 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6602288B2 (ja) 2013-04-03 2019-11-06 フジフィルム セルラー ダイナミクス，インコーポレイテッド 浮遊液中で内胚葉前駆細胞を培養するための方法および組成物
AU2014256876B2 (en) 2013-04-26 2020-11-12 Cornell, University Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
WO2015058067A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
ES2966757T3 (es) 2014-03-04 2024-04-24 Fate Therapeutics Inc Métodos de reprogramación mejorados y plataformas de cultivo celular
JP2017514793A (ja) * 2014-03-26 2017-06-08 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
CN107429230B (zh) 2015-01-26 2021-11-12 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
SG11201802957PA (en) 2015-10-16 2018-05-30 Fate Therapeutics Inc Platform for the induction & maintenance of ground state pluripotency
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
IL258899B2 (en) 2015-10-30 2024-03-01 Univ California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
SG11201908660RA (en) 2017-05-18 2019-10-30 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
JP7253500B2 (ja) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド ピリミジン誘導体
IL270623B2 (en) 2017-05-18 2023-03-01 Idorsia Pharmaceuticals Ltd History of phenyl as pge2 receptor modulators
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
CN111372576A (zh) 2017-11-17 2020-07-03 塞尔利克斯生物私人有限公司 用于治疗眼部病症的组合物和方法
RU2020124116A (ru) * 2017-12-22 2022-01-25 Хиберселл, Инк. Производные арил-бипиридинамина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
US12303498B2 (en) * 2018-03-23 2025-05-20 Cytoo ALK5 inhibitors as skeletal muscle hypertrophy inducers
CA3153456A1 (en) 2019-10-02 2021-04-08 Stefanie Fluckiger-Mangual Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US12006290B2 (en) 2020-03-19 2024-06-11 Caamtech, Inc. Crystalline norpsilocin compounds
JP2023519673A (ja) * 2020-03-31 2023-05-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 置換ピリミジンおよび使用方法
CA3181162A1 (en) 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases
EP4171557A1 (en) 2020-06-25 2023-05-03 Tolremo Therapeutics AG Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
KR20230027294A (ko) * 2020-06-25 2023-02-27 톨레모 테라퓨틱스 아게 섬유성 질환의 치료, 개선 또는 예방을 위한 헤테로사이클릭 유도체, 약학 조성물 및 그들의 용도
DK4182308T3 (da) 2020-07-15 2024-10-21 Chiesi Farm Spa Pyridazinylamino-derivater som ALK5-inhibitorer
ES2982017T3 (es) 2020-07-15 2024-10-14 Chiesi Farm Spa Derivados de pirido-oxazina como inhibidores de ALK5
EP4182323B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine amino derivatives as alk5 inhibitors
WO2022136221A1 (en) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
US20250011299A1 (en) 2021-09-21 2025-01-09 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors
AU2024343386B2 (en) 2023-11-03 2025-12-18 Axent Biosciences Inc. Thermoreversible polymers with improved stability and methods and uses thereof
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative
NL2037929B1 (en) 2024-06-11 2026-01-12 Prinses Maxima Centrum Voor Kinderoncologie B V Brain Organoid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1345640A (en) * 1971-02-01 1974-01-30 Shell Int Research Piperazinyl pyrimidines
WO1998037079A1 (en) * 1997-02-19 1998-08-27 Berlex Laboratories, Inc. N-heterocyclic derivatives as nos inhibitors
JP2003524595A (ja) * 1998-07-08 2003-08-19 モナシュ ユニバーシティ 薬 剤
IL150420A0 (en) * 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
RU2004138819A (ru) * 2002-05-30 2005-06-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ jak и cdk2
TW200417547A (en) * 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
GB0313915D0 (en) 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
CN1820001A (zh) * 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
BRPI0417478A (pt) 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2007271964A1 (en) 2008-01-17
RU2009104770A (ru) 2010-08-27
ES2393932T3 (es) 2013-01-02
JP2009543765A (ja) 2009-12-10
KR20090018213A (ko) 2009-02-19
AU2007271964B2 (en) 2012-01-19
TW200821297A (en) 2008-05-16
AR061974A1 (es) 2008-08-10
US7989458B2 (en) 2011-08-02
EP2044056A1 (en) 2009-04-08
JP4960450B2 (ja) 2012-06-27
KR101172936B1 (ko) 2012-08-16
PT2044056E (pt) 2012-12-05
MX2009000310A (es) 2009-01-26
BRPI0714409A2 (pt) 2013-03-12
CL2007002043A1 (es) 2008-06-13
CA2657227A1 (en) 2008-01-17
EP2044056B1 (en) 2012-08-22
WO2008006583A1 (en) 2008-01-17
US20090209539A1 (en) 2009-08-20
RU2485115C2 (ru) 2013-06-20
PL2044056T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
PE20080944A1 (es) Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5)
PE20091728A1 (es) Derivados de cicloheptapiridina como antagonistas de receptor de cgrp
PE20080695A1 (es) Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
MX2009004807A (es) Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20090717A1 (es) Derivados de quinolina como inhibidores de la pi3 quinasa
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20091486A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
MX2012004848A (es) Compuestos heterociclicos triciclicos.
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
PE20091687A1 (es) Derivados de piridina o pirazina como inhibidores de cinasa-pi-3
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
NO20085257L (no) Purinonderivater som HM74a-agonister
NZ590954A (en) Compounds as kinase inhibitors
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.

Legal Events

Date Code Title Description
FD Application declared void or lapsed